JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267011

Human TRIM34 (RNF21/IFP1) knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TRIM34 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 8 and 1 bp insertion in exon 8. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)

Allele-2 : 1 bp insertion in exon 8.

Sanger Sequencing - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)
  • Sanger seq

Unknown

Sanger Sequencing - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)

Allele-1 : 1 bp deletion in exon8

Cell Culture - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)
  • Cell Culture

Unknown

Cell Culture - Human TRIM34 (RNF21/IFP1) knockout A549 cell line (AB267011)

Representative images of TRIM34 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS XL Core microscope.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 8 and 1 bp insertion in exon 8

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267011-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267011 Human TRIM34 (RNF21/IFP1) knockout A549 cell line", "number":"AB267011-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267011-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267011-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267011-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267011 Human TRIM34 (RNF21/IFP1) knockout A549 cell line", "number":"AB267011-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267011-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267011 Human TRIM34 (RNF21/IFP1) knockout A549 cell line", "number":"AB267011-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267011-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267011 Human TRIM34 (RNF21/IFP1) knockout A549 cell line", "number":"AB267011-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TRIM34
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RNF21 also known as IFP1 is a human protein with a molecular weight of approximately 43 kDa. It belongs to the RING finger protein family functioning as an E3 ubiquitin ligase. Members of this family typically regulate protein degradation through the ubiquitin-proteasome system. RNF21 is widely expressed in various tissues including the brain liver and heart. This expression suggests important roles across different physiological contexts.
Biological function summary

The E3 ubiquitin ligase activity of RNF21 contributes to the regulation of protein homeostasis. RNF21 potentially participates in forming larger protein complexes which could be involved in cellular processes like cell cycle regulation. By tagging specific proteins for degradation RNF21 maintains cellular protein equilibrium. This process impacts various cellular functions including signal transduction and cellular stress responses.

Pathways

The function of RNF21 integrates within the ubiquitin-proteasome pathway and connects to protein turnover. This pathway involves numerous proteins such as ubiquitin-conjugating enzymes which work alongside RNF21. Additionally RNF21 may intersect with signaling pathways related to protein stability where it collaborates with proteins like SCF complexes which also function in protein degradation.

RNF21 has connections to neurodegenerative diseases such as Alzheimer's disease where protein aggregation becomes problematic. Aberrant protein degradation can exacerbate these disease conditions. RNF21's interactions with proteins like tau which is involved in Alzheimer's pathology illustrate its potential influence. Moreover its role in inflammatory responses might link RNF21 to disorders like rheumatoid arthritis where improper protein regulation plays a role.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com